Evidence map›Paper›PMID 41808715›Full record

ArticleTranslational lung cancer research2026

Higher proximity of PD-L1

Yimin Zhao, Yushan Yan, Liying Yang, Miaoqing Zhao, Hongtu Yuan, Jiaxiao Geng, Li Wu, Hao Yang, Qianhui Chen, Fanghan Cao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yimin Zhao *Department of Nuclear Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Yushan Yan *Department of Oncology, The Affiliated Hospital of Southwest Medical University, Southwest Medical University, Luzhou, China.
Liying YangDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Miaoqing ZhaoDepartment of Pathology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Hongtu YuanDepartment of Pathology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Jiaxiao GengDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Li WuDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Southwest Medical University, Luzhou, China.
Hao YangDepartment of Nuclear Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Qianhui ChenDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Fanghan CaoDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Ligang XingDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Xiaorong SunDepartment of Nuclear Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although neoadjuvant chemoimmunotherapy (NCIT) improves outcomes in resectable non-small cell lung cancer (NSCLC), traditional biomarkers like programmed death-ligand 1 (PD-L1) expression are insufficient for accurate patient selection. This study aimed to investigate the spatial interaction between specific T-cell subsets and PD-L1 Methods: We retrospectively recruited 44 patients with stage IIA-IIIB NSCLC who had NCIT at Shandong Cancer Hospital and Institute from January 2021 to June 2023. Pre-treatment specimens were subjected to multicolor immunofluorescence staining (panel 1: CK/PD-L1/PD-1/CD8/CD103/CD4/FOXP3; panel 2: CK/CD8/CD4/α-SMA/CD31/HIF-1α) to quantify PD-L1 Results: Among the 44 patients, 52.3% showed a response. Compared with non-responders, responders had closer distances between PD-L1 Conclusions: T cells interacting with PD-L1

Indexed as

hypoxia-inducible factor-1α (HIF-1α)neoadjuvant chemoimmunotherapy (NCIT)Non-small cell lung cancer (NSCLC)spatial interactiontissue-resident memory T cells

Identifiers

PMID41808715
PMCPMC12969226

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.